25 June 2026
: Case report
[In Press] Histiocytic Sarcoma With Striking Clinical Improvement
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare disease
Nur FarhanahDOI: 10.12659/AJCR.952214
Am J Case Rep In Press; DOI: 10.12659/AJCR.952214
Available online: 2026-06-25, In Press, Corrected Proof
Publication in the "In-Press" formula aims at speeding up the public availability of the pending manuscript while waiting for the final publication. The assigned DOI number is active and citable. The availability of the article in the Medline, PubMed and PMC databases as well as Web of Science will be obtained after the final publication according to the journal schedule
Abstract
BACKGROUND
Histiocytic sarcoma (HS) is a rare and aggressive hematopoietic malignancy characterized by histiocytic cell proliferation. Its rarity and nonspecific presentation create significant diagnostic and therapeutic challenges, particularly in HIV-positive patients.
CASE REPORT
An HIV-positive man in his late 20s from a rural area and low-income background, referred from a district hospital, presented with asymptomatic nodular and crateriform lesions on the face, thorax, and back, characterized by central keratosis, crust, and erythematous-violaceous infiltrated edges. Histopathological and immunohistochemical analysis confirmed the diagnosis of histiocytic sarcoma, with tumor cells positive for CD68. Considering the patient’s multisystem involvement, 6 to 8 cycles of CHOP chemotherapy were recommended. However, the patient declined systemic therapy and opted for a watch-and-wait approach. No invasive procedures such as bone marrow biopsy were performed, as the patient exhibited no constitutional symptoms or cytopenias. Clinical follow-up over 6 months revealed significant improvement in tumor size and overall condition. This favorable outcome may have been partially influenced by immune reconstitution associated with ongoing antiretroviral therapy (ART), although a direct causal relationship cannot be established. Management of histiocytic sarcoma remains controversial due to the lack of established guidelines and variability in natural history. For this patient, a non-aggressive, observational approach yielded favorable outcomes, challenging the conventional use of systemic chemotherapy in all cases of multisystem involvement. Regular clinical follow-up has been integral to monitoring disease progression.
CONCLUSIONS
This report underscores the diagnostic and therapeutic challenges associated with histiocytic sarcoma and highlights the importance of a multidisciplinary team approach involving infectious disease specialists and hematology-oncology experts in achieving optimal clinical outcomes. Despite declining systemic treatment, the patient had a favorable clinical outcome.
Keywords: Histiocytic Sarcoma; HIV Infections; Immunohistochemistry; Hematology; Sarcoma, Histiocytic; Skin Neoplasms; Watchful Waiting; Case Reports; CHOP Protocol
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.952791
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.952909
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950868
Most Viewed Current Articles
07 Dec 2021 : Case report
22,759,422
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
175,936
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
120,499
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
65,510
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






